BRAF and melanoma: Three MEK inhibitors, including trametinib (GSK1120212), cobimetinib (XL518), and binimetinib (MEK162), are approved in combination with BRAF inhibitors for the treatment of patients with advanced melanoma harboring BRAF mutations (V600E or V600K).